Maximus Inc (MMS)

This article identifies three underfollowed small-cap financial stocks—Maximus (MMS), Exzeo Group (XZO), and HCI Group (HCI)—that could thrive in a high-interest-rate environment. These companies, highlighted from the "High Quality Undiscovered Gems" screener, offer resilience and growth potential by operating in areas like government services modernization and InsurTech, despite potential risks like contract concentration or reliance on external factors. The article suggests these stocks could be valuable additions to a long-term portfolio before they gain widespread institutional attention.

Maximus Inc. (MMS) reported Q3 fiscal results and updated its full-year 2026 guidance, with revenue projected to be US$5.2–US$5.35 billion and net income US$376–US$392 million. The company reaffirmed its focus on disciplined acquisitions and share repurchases within a target net debt ratio of 2x–3x. This strategy aims to expand capabilities and customer access, driving revenue synergies and maintaining financial stability amid potential contract volume and budget pressures.

Maximus, Inc. reported its Q3 results with strong revenue and net income, and updated its 2026 full-year guidance, which includes revenue between US$5.2 billion and US$5.35 billion. The company emphasized its continued focus on disciplined acquisitions and share repurchases, aiming for revenue synergies while maintaining a net debt ratio of 2x-3x. This strategy reinforces the investment narrative centered on government outsourcing, margin improvement through technology, and controlled capital deployment, with some analysts projecting significant upside to its current stock price.

Maximus Inc. (MMS) reported strong Q3 fiscal 2026 results with revenue aligning with expectations and adjusted EPS showing an increase. Despite improvements in adjusted EBITDA margin and US Federal Services operating margin, a customer-directed pause in performance incentives on the VA Medical Disability Exam (VAMDE) program is expected to negatively impact Q4 and Q1 fiscal 2027 earnings, leading to a revised EPS guidance. The company faces challenges including declining revenues in some segments, negative cash flow from operations due to administrative delays, and a slower pace of new contract signings.

Maximus (MMS) has drawn investor attention after its fiscal 2026 third-quarter results and updated guidance indicated revenue near the lower end of expectations, citing contract delays and weaker award conversion. Despite a 35.17% year-to-date share price decline, the company is still considered 43.9% undervalued with a fair value of $100 based on expectations of expanded demand due to new federal legislation. However, this valuation depends on timely contract rollouts and assumes no insourcing or client shifts to competitors.